Loading...
•
Mar 31, 2022
Acacia Q1 2022 Earnings Report
Acacia Research's financial performance reflected revenue growth driven by the Printronix acquisition, offset by net losses due to unrealized losses on equity securities, while also making progress on share repurchases and receiving FDA approval for Mycovia Pharmaceuticals' drug.
Key Takeaways
Acacia Research reported a revenue of $13.5 million, up from $5.8 million in the same quarter last year, which includes $10.9 million from Printronix. The company experienced a GAAP Net Loss of $73.3 million, or ($1.61) per diluted share, compared to a net loss of $164.5 million, or ($2.81) per diluted share, in the first quarter of last year. The company completed $15.0 million of share repurchases and anticipates receiving a $26 million milestone payment from Mycovia Pharmaceuticals.
Total revenues were $13.5 million, compared to $5.8 million in the same quarter last year, including $10.9 million from Printronix.
Recorded $66.9 million in realized gains during the quarter, including $59.5 million from the Life Sciences Portfolio.
Completed $15.0 million of share repurchase under authorization announced in December 2021, repurchasing 3.1 million shares at an average price of $4.80.
GAAP Net Loss of $(73.3) million, or ($1.61) per diluted share, compared to net loss of $(164.5) million, or $(2.81) per diluted share, in the first quarter of last year.
Revenue by Segment
Forward Guidance
Acacia anticipates attractive acquisition opportunities due to dislocations in the capital markets, leveraging its strong capital position and partnership with Starboard Value, LP.
Positive Outlook
- Strong capital position
- Team of seasoned M&A professionals
- Strategic partners at Starboard Value, LP
- Attractive acquisitions
- Stock represents attractive value relative to book value
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...